| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
101,390,000 |
| Market
Cap: |
1.64(B) |
| Last
Volume: |
668,805 |
Avg
Vol: |
666,996 |
| 52
Week Range: |
$12.32 - $16.78 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Innoviva is a company with a portfolio of royalties and other healthcare assets. Co.'s royalty portfolio contains respiratory assets partnered with Glaxo Group Limited (GSK), including RELVAR®/BREO® ELLIPTA®, ANORO® ELLIPTA® and TRELEGY® ELLIPTA®. Co. is entitled to royalty payments made by GSK under its agreements that assigned to Theravance Respiratory Company, LLC (TRC), including TRELEGY® ELLIPTA® and any other product or combination of products that may be discovered or developed in the future under the Long-Acting Beta2 Agonist Collaboration Agreement and the Strategic Alliance Agreement with GSK, which have been assigned to TRC other than RELVAR®/BREO® ELLIPTA® and ANORO® ELLIPTA®.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
664,000 |
| Total Buy Value |
$0 |
$0 |
$0 |
$8,468,005 |
| Total People Bought |
0 |
0 |
0 |
2 |
| Total Buy Transactions |
0 |
0 |
0 |
12 |
| Total Shares Sold |
0 |
0 |
10,994 |
10,994 |
| Total Sell Value |
$0 |
$0 |
$153,810 |
$153,810 |
| Total People Sold |
0 |
0 |
1 |
1 |
| Total Sell Transactions |
0 |
0 |
1 |
1 |
| End Date |
2024-03-21 |
2023-12-19 |
2023-06-20 |
2022-06-20 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Brinkley David L |
Head of Business Dev. |
• – – |
2010-09-14 |
4 |
S |
$15.12 |
$29,938 |
D/D |
(1,980) |
32,351 |
|
- |
|
| Mammen Mathai |
SVP, Research & Early Clin Dev |
• – – |
2010-09-07 |
4 |
OE |
$8.53 |
$54,995 |
D/D |
6,451 |
124,017 |
|
- |
|
| Mammen Mathai |
SVP, Research & Early Clin Dev |
• – – |
2010-09-01 |
4 |
S |
$12.84 |
$56,701 |
D/D |
(4,416) |
117,566 |
|
- |
|
| Aguiar Michael W |
Sr VP, Chief Financial Officer |
• – – |
2010-08-20 |
4 |
D |
$14.00 |
$27,370 |
D/D |
(1,955) |
109,915 |
|
- |
|
| Shafer Bradford J |
Sr VP, Gen. Counsel, Secretary |
• – – |
2010-08-20 |
4 |
D |
$14.00 |
$21,602 |
D/D |
(1,543) |
247,577 |
|
- |
|
| Brinkley David L |
Head of Business Dev. |
• – – |
2010-08-20 |
4 |
D |
$14.00 |
$12,698 |
D/D |
(907) |
34,331 |
|
- |
|
| Mammen Mathai |
SVP, Research & Early Clin Dev |
• – – |
2010-08-20 |
4 |
D |
$14.00 |
$23,394 |
D/D |
(1,671) |
121,982 |
|
- |
|
| Winningham Rick E |
Chief Executive Officer |
• • – |
2010-08-20 |
4 |
D |
$14.00 |
$50,736 |
D/D |
(3,624) |
159,378 |
|
- |
|
| Levine Arnold J |
Director |
– • – |
2010-06-17 |
4 |
A |
$0.00 |
$0 |
D/D |
29,192 |
47,192 |
|
- |
|
| Brinkley David L |
Head of Business Dev. |
• – – |
2010-06-15 |
4 |
S |
$15.45 |
$517,822 |
D/D |
(33,516) |
35,238 |
|
- |
|
| Brinkley David L |
Head of Business Dev. |
• – – |
2010-06-15 |
4 |
OE |
$8.53 |
$285,724 |
D/D |
33,516 |
68,754 |
|
- |
|
| Brinkley David L |
Head of Business Dev. |
• – – |
2010-06-14 |
4 |
S |
$15.65 |
$524,525 |
D/D |
(33,516) |
35,238 |
|
- |
|
| Brinkley David L |
Head of Business Dev. |
• – – |
2010-06-14 |
4 |
OE |
$8.53 |
$285,724 |
D/D |
33,516 |
68,754 |
|
- |
|
| Blum Leonard M |
Sr VP, Chief Comm. Officer |
• – – |
2010-05-20 |
4 |
D |
$13.02 |
$21,952 |
D/D |
(1,686) |
156,932 |
|
- |
|
| Shafer Bradford J |
Sr VP, Gen. Counsel, Secretary |
• – – |
2010-05-20 |
4 |
D |
$13.02 |
$20,103 |
D/D |
(1,544) |
249,120 |
|
- |
|
| Mammen Mathai |
SVP, Research & Early Clin Dev |
• – – |
2010-05-20 |
4 |
D |
$13.02 |
$21,782 |
D/D |
(1,673) |
123,653 |
|
- |
|
| Aguiar Michael W |
Sr VP, Chief Financial Officer |
• – – |
2010-05-20 |
4 |
D |
$13.02 |
$25,454 |
D/D |
(1,955) |
111,870 |
|
- |
|
| Brinkley David L |
Head of Business Dev. |
• – – |
2010-05-20 |
4 |
D |
$13.02 |
$11,822 |
D/D |
(908) |
35,238 |
|
- |
|
| Winningham Rick E |
Chief Executive Officer |
• • – |
2010-05-20 |
4 |
D |
$13.02 |
$47,198 |
D/D |
(3,625) |
163,002 |
|
- |
|
| Whitesides George M |
Director |
– • – |
2010-04-27 |
4 |
A |
$0.00 |
$0 |
D/D |
6,000 |
555,419 |
|
- |
|
| Young William D |
Director |
– • – |
2010-04-27 |
4 |
A |
$0.00 |
$0 |
D/D |
6,000 |
18,000 |
|
- |
|
| Waltrip William H |
Director |
– • – |
2010-04-27 |
4 |
A |
$0.00 |
$0 |
D/D |
6,000 |
50,258 |
|
- |
|
| Ringrose Peter S |
Director |
– • – |
2010-04-27 |
4 |
A |
$0.00 |
$0 |
D/D |
12,000 |
12,000 |
|
- |
|
| Drazan Jeffrey M |
Director |
– • – |
2010-04-27 |
4 |
A |
$0.00 |
$0 |
D/D |
6,000 |
45,866 |
|
- |
|
| Levine Arnold J |
Director |
– • – |
2010-04-27 |
4 |
A |
$0.00 |
$0 |
D/D |
6,000 |
18,000 |
|
- |
|
704 Records found
|
|
Page 22 of 29 |
|
|
0.06 (0.37%) 
